

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Autoimmune disease				
Autoimmune disease; multiple sclerosis (MS)	Chemokine CXC motif ligand 11 (CXCL11)	<p>Mouse studies suggest low doses of CXCL11 could be useful for treating autoimmune conditions such as MS. In a mouse model of experimental autoimmune encephalomyelitis (EAE), a Cxcl11-Ig fusion molecule induced remission and prevented relapse, whereas a Cxcl10 (Ip-10)-Ig fusion molecule, control IgG or saline did not. In an EAE mouse model with <i>Cxcl11</i> deficiency, treatment with low doses of Cxcl11 suppressed development of EAE, whereas saline treatment did not. Next steps could include evaluating CXCL11-based therapies in additional models of autoimmune disease.</p> <p>SciBX 7(18); doi:10.1038/scibx.2014.514 Published online May 8, 2014</p>	<p>Patented; available for licensing from Technion-Israel Institute of Technology Contact: Orit Shaked, Technion-Israel Institute of Technology, Haifa, Israel e-mail: oshaked@tx.technion.ac.il</p>	<p>Zohar, Y. <i>et al.</i> <i>J. Clin. Invest.</i>; published online April 8, 2014; doi:10.1172/JCI71951 Contact: Nathan Karin, Technion-Israel Institute of Technology, Haifa, Israel e-mail: nkarin10@gmail.com</p>